Discussion about this post

User's avatar
Manfred Johann Schmuckerschlag's avatar

This I just got:

Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany—Results from the SeBluCo Study 2020–2022

https://www.mdpi.com/2076-0817/12/4/551

Offergeld R, Preußel K, Zeiler T, Aurich K, Baumann-Baretti BI, Ciesek S, Corman VM, Dienst V, Drosten C, Görg S, et al.

Pathogens 2023, 12(4), 551

https://doi.org/10.3390/pathogens12040551

Published: 2 April 2023

-

"Conflicts of Interest

Victor M. Corman is named together with Euroimmun on a patent application filed recently regarding the diagnosis of SARS-CoV-2 by antibody testing (“Methods and reagents for diagnosis of SARS-CoV-2 infection.” Patent application no. EP3809137A1). All other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results."

-

To cite just an excerpt:

"

3.1. Total Study-Wide Seroprevalence over Time

In CW 19–22 (May) 2020, the total adjusted seroprevalence was 1.2% (95% CI: 0.6–2.1%). It then fell to 0.6% (95% CI: 0.4–0.9%) in CW 27–34 (July–August). Afterwards, it rose again but stayed below 2% until CW 47–50 (December), where it reached 1.8% (95% CI: 1.4–2.2%). At the end of 2020, the total seroprevalence started to rise and reached 18.1% (95% CI: 17.2–19.0%) in CW 14–17 (April) 2021. In CW 36–37 (September) 2021, total seroprevalence was estimated to be 89.4% (95% CI: 88.4.3–90.4%) and in CW 17–20 (April/May) 2022 100% (95% CI: 98.5–100) (Figure 2)."

-

Which mneans data were available prior to the debate in regards to the vaccine mandate in Gemany/in Austria

-

And then - the patent mentioned.

EP3809137A1

Methods and reagents for diagnosis of sars-cov-2 infection

https://patents.google.com/patent/EP3809137A1/en

https://patentimages.storage.googleapis.com/db/67/45/21010f482f2c53/EP3809137A1.pdf

Inventor: Katja STEINHAGEN - Claudia MESSING - Erik LATTWEIN - Konstanze Stiba - Fabian LINDHORST - Eva Neugebauer - Marcel Müller - Victor CORMAN

Current Assignee: Charite Universitaetsmedizin Berlin - Euroimmun Medizinische Labordiagnostika AG

2021-04-21 Publication of EP3809137A1

-

The public private partnership at work.

Expand full comment
Dr Mike Yeadon's avatar

With the benefit of hindsight, obviously no analytical method can detect non-existent things.

It doesn’t matter if the original Corman-Drosten paper had described a method that was claimed to be technically less flawed.

The Corman-Drosten Review paper described ten technical flaws with the methodology in the Corman-Drosten paper.

I now think they are irrelevant.

I also think I’ve allowed myself to be misused.

By simply contesting details of the PCR analytical method, I have inadvertently underwritten the idea of viruses and of pandemics.

Those who’ve followed my evolving understanding of acute respiratory illnesses know that I no longer believe in the virus cause & contagion.

Under no circumstances should anyone agree to “diagnostic tests”, comply with restrictive “countermeasures” or roll up their sleeve to be “vaccinated”.

Expand full comment
19 more comments...

No posts